Suppr超能文献

改良两步法颊侧浸润 4%阿替卡因用于有症状不可复性牙髓炎下颌磨牙的主、辅助麻醉效果:一项随机临床试验。

Primary and supplementary anesthetic efficacy of a modified two-step buccal infiltration of 4% articaine in mandibular molars with symptomatic irreversible pulpitis: a randomized clinical trial.

机构信息

Iranian Center for Endodontic Research, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Department of Endodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Clin Oral Investig. 2023 Dec 26;28(1):33. doi: 10.1007/s00784-023-05417-0.

Abstract

OBJECTIVES

To evaluate a modified two-step buccal infiltration (MBI) of 1.7 mL 4% articaine as primary or supplemental anesthesia in mandibular first and second molars diagnosed with symptomatic irreversible pulpitis (SIP).

MATERIALS AND METHODS

One hundred and eight patients with SIP were randomly assigned to one of three groups (n = 36). They were given an inferior alveolar nerve block (IANB) of 2% lidocaine with 1:80.000 epinephrine or a primary MBI of 4% articaine with 1:100.000 epinephrine in the IANB and MBI groups, respectively. Patients in the IANB + MBI group received an IANB followed by an MBI. Pain levels during the injection, access cavity preparation, and initial filing were recorded on the Heft-Parker visual analog scale (HP-VAS). No or mild pain (HP-VAS ≤ 54) upon access cavity preparation and initial filing was considered a success. Chi-square and Kruskal-Wallis tests were used to analyze the data.

RESULTS

MBI (77.8%) and IANB + MBI (94.4%) had both significantly higher success rates than IANB (50.0%) (P < .001). However, when the Bonferroni adjustment was applied, there was no statistically significant difference between the MBI and IANB + MBI techniques (P = .041 > .017). MBI was associated with significantly less injection pain than IANB (P < .001).

CONCLUSIONS

Both primary and supplemental MBI with 4% articaine were superior to IANB with 2% lidocaine in mandibular first and second molars diagnosed with SIP. Further research may be needed to confirm the findings of this study.

CLINICAL RELEVANCE

The findings of this study suggest that supplemental or primary MBI can be a clinically viable alternative to IANB, which has a relatively low success rate when managing mandibular molars diagnosed with SIP.

摘要

目的

评估改良两步颊侧浸润(MBI)1.7ml 4%阿替卡因作为诊断为症状性不可复性牙髓炎(SIP)的下颌第一和第二磨牙的主要或辅助麻醉。

材料和方法

108 例 SIP 患者随机分为三组(n=36)。他们分别接受下牙槽神经阻滞(IANB)2%利多卡因加 1:80000 肾上腺素或 IANB 组和 MBI 组 4%阿替卡因加 1:100000 肾上腺素的初级 MBI。IANB+MBI 组患者先接受 IANB,再接受 MBI。记录注射时、开髓时和初始填充时的 Heft-Parker 视觉模拟量表(HP-VAS)疼痛水平。开髓和初始填充时无或轻度疼痛(HP-VAS≤54)被认为是成功的。使用卡方检验和 Kruskal-Wallis 检验分析数据。

结果

MBI(77.8%)和 IANB+MBI(94.4%)的成功率均明显高于 IANB(50.0%)(P<0.001)。然而,当应用 Bonferroni 校正时,MBI 和 IANB+MBI 技术之间没有统计学上的显著差异(P=0.041>0.017)。MBI 与 IANB 相比,注射疼痛明显减轻(P<0.001)。

结论

在诊断为 SIP 的下颌第一和第二磨牙中,初级和辅助 MBI 用 4%阿替卡因均优于 IANB 用 2%利多卡因。需要进一步的研究来证实本研究的结果。

临床相关性

本研究结果表明,对于诊断为 SIP 的下颌磨牙,MBI 可作为 IANB 的一种可行替代方案,后者的成功率相对较低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验